B. Braun and Kerma Medical have come together to collaborate on improving the delivering and development of healthcare services and products.

India: B. Braun Medical Inc., a renowned medical and pharmaceutical device company supplying the healthcare products globally and Kerma Medical, another company specializing in health care supplies, have announced collaboration. The collaboration has been made with the aim of developing and improving the delivery of healthcare products and services. Both the companies will focus on providing healthcare services to minorities and underserved communities.

The collaboration is expected to span across a range of applications such as sustainable manufacturing, strategic sourcing, co-marketing opportunities, product novel product development and diversity programs. Even though the product lines of both companies are different, some of the common values have strengthen the bond between the two. They will identify the areas and communities in need and will collaborate with healthcare providers and programs to provide improved healthcare products and services.

Chief Sales Officer and Senior Vice President of B. Braun said, " Kerma has established itself as one of the premier minority, veteran-owned companies in the healthcare industry, " He further added, “Our collaboration gives us the opportunity to forge new relationships with a set of customers in the commercial market that have unique healthcare needs. With Kerma, we will improve our ability to understand those customers and know how to serve them better, while enhancing our diversity engagement goals and initiatives.”

According to TechSci Research, the collaboration is expected to cater to the communities which are underserved and are unable to access the modern healthcare services. Expanding the areas of reach will aid the business expansion of both the companies and will generate benefit mutually. Furthermore, the collaboration will improve the healthcare infrastructure and will forge reliable relationships with customers with the provision of medical products, nutrition, pharmacy admixtures and other healthcare products.

According to the report published by TechSci Research, “Global Antimalarial Drugs Market By Drug Type (Quinine, Chloroquine, Proguanil, Amodiaquine, Mefloquine, Hydroxychloroquine, Pyrimethamine, Others), By Drug Class (Aryl Aminoalcohol Compounds, Antifolate Compounds, Artemisinin Compounds, Antimicrobials), By Route of Administration (Oral, Powder Inhalation, Intravenous Administration), By Malaria Type (Plasmodium Falciparum, Plasmodium Malariae, Plasmodium Vivax, Plasmodium Ovale, Plasmodium Knowlesi), By Application (Prevention, Treatment of Malaria), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, E-Commerce, Others), By Region, Forecast & Opportunities, 2025”, global antimalarial drugs market is expected to register double digit CAGR during the forecast period owing to increasing prevalence of malaria and COVID-19 around the world. According to various studies, tablets containing hydroxychloroquine have the ability to inhibit the virus that causes corona. This is a major factor fueling the demand for antimalarial drugs across various nations. Moreover, the growing focus of governments in various economies towards the treatment of COVID-19 is also a key factor for growth of antimalarial drugs market. With increasing research and development activities to develop new antimalarial drugs, the market is expected to witness significant growth in the coming years.